Sera Prognostics Debt to Equity Ratio 2021-2024 | SERA
Current and historical debt to equity ratio values for Sera Prognostics (SERA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sera Prognostics debt/equity for the three months ending December 31, 2024 was 0.00.
| Sera Prognostics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-12-31 | $0.03B | $0.05B | 0.52 |
| 2024-09-30 | $0.02B | $0.06B | 0.45 |
| 2024-06-30 | $0.03B | $0.06B | 0.42 |
| 2024-03-31 | $0.03B | $0.07B | 0.39 |
| 2023-12-31 | $0.03B | $0.07B | 0.36 |
| 2023-09-30 | $0.02B | $0.08B | 0.19 |
| 2023-06-30 | $0.02B | $0.08B | 0.19 |
| 2023-03-31 | $0.02B | $0.09B | 0.17 |
| 2022-12-31 | $0.02B | $0.10B | 0.18 |
| 2022-09-30 | $0.01B | $0.11B | 0.09 |
| 2022-06-30 | $0.01B | $0.12B | 0.07 |
| 2022-03-31 | $0.01B | $0.13B | 0.06 |
| 2021-12-31 | $0.01B | $0.14B | 0.06 |
| 2021-09-30 | $0.00B | $0.15B | 0.02 |
| 2021-06-30 | $0.00B | $0.09B | 0.04 |
| 2021-03-31 | $0.00B | $0.00B | 0.00 |
| 2020-12-31 | $0.00B | 0.00 | |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.085B | $0.000B |
| Sera Prognostics Inc. is a women's health diagnostics company. It focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients. Sera Prognostics Inc. is based in SALT LAKE CITY. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.417B | 25.21 |
| Elevance Health (ELV) | United States | $84.565B | 10.91 |
| CVS Health (CVS) | United States | $75.952B | 9.44 |
| Cencora (COR) | United States | $54.132B | 18.82 |
| DiDi Global (DIDIY) | China | $21.231B | 32.22 |
| Natera (NTRA) | United States | $20.665B | 0.00 |
| BioMerieux (BMXMF) | France | $15.263B | 0.00 |
| Solventum (SOLV) | United States | $12.308B | 13.03 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.132B | 0.00 |
| Doximity (DOCS) | United States | $11.108B | 57.77 |
| CochLear (CHEOY) | Australia | $11.097B | 0.00 |
| Revvity (RVTY) | United States | $10.729B | 18.46 |
| ICON (ICLR) | Ireland | $10.678B | 9.93 |
| Viatris (VTRS) | United States | $9.882B | 3.40 |
| Avantor (AVTR) | United States | $8.756B | 12.72 |
| HealthEquity (HQY) | United States | $8.482B | 41.73 |
| Medpace Holdings (MEDP) | United States | $8.385B | 22.27 |
| Sonic Healthcare (SKHHY) | Australia | $8.090B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.825B | 13.37 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.093B | 37.89 |
| Bausch + Lomb (BLCO) | Canada | $4.082B | 24.06 |
| Sotera Health (SHC) | United States | $3.636B | 20.66 |
| Alignment Healthcare (ALHC) | United States | $2.950B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.918B | 37.95 |
| Concentras Parent (CON) | United States | $2.739B | 15.83 |
| Organon (OGN) | United States | $2.090B | 2.22 |
| Ardent Health Partners (ARDT) | United States | $2.084B | 8.88 |
| Premier (PINC) | United States | $2.056B | 14.07 |
| Progyny (PGNY) | United States | $1.874B | 41.24 |
| GeneDx Holdings (WGS) | United States | $1.696B | 65.33 |
| PACS (PACS) | United States | $1.666B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.638B | 30.50 |
| Teladoc Health (TDOC) | United States | $1.288B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.219B | 9.27 |
| Agilon Health (AGL) | United States | $1.105B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.054B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.892B | 13.93 |
| Nutex Health (NUTX) | United States | $0.884B | 13.36 |
| AMN Healthcare Services Inc (AMN) | United States | $0.833B | 7.80 |
| QDM (QDMI) | Hong Kong, SAR China | $0.691B | 0.00 |
| Embecta (EMBC) | United States | $0.677B | 4.56 |
| InnovAge Holding (INNV) | United States | $0.554B | 0.00 |
| Enhabit (EHAB) | United States | $0.536B | 44.08 |
| Auna S.A (AUNA) | Luxembourg | $0.514B | 13.61 |
| Sonida Senior Living (SNDA) | United States | $0.496B | 0.00 |
| LifeMD (LFMD) | United States | $0.434B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.358B | 0.00 |
| SBC Medicals (SBC) | United States | $0.348B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.203B | 0.00 |
| Beauty Health (SKIN) | United States | $0.185B | 0.00 |
| Oncology Institute (TOI) | United States | $0.179B | 0.00 |
| DocGo (DCGO) | United States | $0.143B | 23.33 |
| So-Young (SY) | China | $0.086B | 0.00 |
| OncoCyte (OCX) | United States | $0.074B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
| KindlyMD (KDLY) | United States | $0.046B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.033B | 0.00 |
| Biodesix (BDSX) | United States | $0.032B | 0.00 |
| ModivCare (MODV) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |